Skip to main content
. 2024 Feb 3;15:1015. doi: 10.1038/s41467-024-45160-y

Fig. 2. Study design.

Fig. 2

Abbreviation: TNBC triple-negative breast cancer, TFI treatment-free interval, ECOG PS Eastern Cooperative Oncology Group performance status, DL dose level, ORR objective response rate, DoR duration of response, CBR clinical benefit rate, DCR disease control rate, PFS progression-free survival, OS overall survival.